Fate Therapeutics (FATE) Receivables (2015 - 2026)
Fate Therapeutics' (FATE) quarterly Receivables came in at $704000.0 in Q1 2026, down 70.74% YoY from $2.4 million in Q1 2025, and down 23.14% on a QoQ basis from $916000.0 in Q4 2025.
Fate Therapeutics (FATE) Receivables (2015 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 10 years of Receivables data on file, last reported at $704000.0 in Q1 2026.
- Quarterly Receivables fell 70.74% year-over-year to $704000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $704000.0 (down 70.74% YoY) and the FY2025 annual result came in at $916000.0, down 74.12% from the prior year.
- Receivables eased to $704000.0 in Q1 2026, from $916000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $38.5 million in Q4 2022 to a low of $682000.0 in Q3 2025.
- A 5-year average of $6.5 million and a median of $2.4 million in 2025 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables soared 343.52% — and 2023, when it plunged 95.25%.
- Tracing FATE's Receivables over 5 years: stood at $38.5 million in 2022, then sank by 95.25% to $1.8 million in 2023, then surged by 93.81% to $3.5 million in 2024, then slumped by 74.12% to $916000.0 in 2025, then fell by 23.14% to $704000.0 in 2026.
- The last three Receivables figures came in at $704000.0 (Q1 2026), $916000.0 (Q4 2025), and $682000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 704,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 704,000.00 |
| Dec 31, 2025 | 916,000.00 |
| Sep 30, 2025 | 682,000.00 |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 2.41 Mn |
| Dec 31, 2024 | 3.54 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 858,000.00 |
| Dec 31, 2023 | 1.83 Mn |
| Sep 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 2.83 Mn |
| Mar 31, 2023 | 13.50 Mn |
| Dec 31, 2022 | 38.48 Mn |
| Sep 30, 2022 | 10.22 Mn |
| Jun 30, 2022 | 13.13 Mn |
| Mar 31, 2022 | 13.85 Mn |
| Dec 31, 2021 | 8.68 Mn |
| Sep 30, 2021 | 7.31 Mn |
| Jun 30, 2021 | 10.30 Mn |